Page last updated: 2024-11-06

vinclozolin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Vinclozolin is a dicarboximide fungicide that has been used widely in agriculture to control diseases in various crops. It is synthesized by a multi-step process involving the condensation of phthalic anhydride with N-methylpyrrolidine, followed by reaction with chlorine. Vinclozolin has been shown to have endocrine-disrupting effects in both humans and animals, particularly affecting the male reproductive system. Its effects include reduced sperm count, testicular atrophy, and prostate abnormalities. These effects are primarily due to its ability to bind to androgen receptors, interfering with the normal function of testosterone. Due to its potential health risks, vinclozolin has been banned in several countries, including the European Union. Despite its ban, vinclozolin is still used in some parts of the world, and its presence in the environment is a concern. The widespread use and environmental persistence of vinclozolin have made it a subject of extensive research, particularly focusing on its toxicological effects, endocrine disruption, and potential long-term impacts on human health and wildlife.'

vinclozolin : A racemate comprising equimolar amounts of (R)- and (S)-vinclozolin. A fungicide used mainly on oilseed rape, vines, fruit and vegetables to control Botrytis, Sclerotinia and Monilia spp. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

3-(3,5-dichlorophenyl)-5-ethenyl-5-methyl-2,4-oxazolidinedione : A member of the class of oxazolidinones that is 5-ethenyl-5-methyl-2,4-oxazolidinedione in which the imide hydrogen is replaced by a 3,5-dichlorophenyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID39676
CHEMBL ID513221
CHEBI ID83732
SCHEMBL ID21851
MeSH IDM0085242

Synonyms (75)

Synonym
HMS1698A06
vinclozoline
2,4-oxazolidinedione, 3-(3,5-dichlorophenyl)-5-ethenyl-5-methyl-
OPREA1_496886
3-(3,5-dichlorphenyl)-5-methyl-5-vinyl-1,3-oxazolidin-2,4-dion [german]
vinclozoline [iso-french]
ornalin
brn 1080192
einecs 256-599-6
bas 352 f
vinclozolin [german]
2,4-oxazolidinedione, 3-(3,5-dichlorophenyl)-5-methyl-5-vinyl-
caswell no. 323c
(+ or -)-3-(3,5-dichlorophenyl)-5-ethenyl-5-methyl-2,4-oxazolidinedione
n-3,5-dichlorophenyl-5-methyl-5-vinyl-1,3-oxazolidine-2,4-dione
ronilan
ccris 9141
vorlan
vinclozolin [bsi:iso]
3-(3,5-dichlorophenyl)-5-ethenyl-5-methyl-2,4-oxazolidinedione
vinchlozoline
hsdb 6747
bas 35204f
epa pesticide chemical code 113201
50471-44-8
vinclozolin
NCGC00163961-01
3-(3,5-dichlorophenyl)-5-methyl-5-vinyl-1,3-oxazolidine-2,4-dione
OPREA1_674584
NCGC00163961-02
3-(3,5-dichlorophenyl)-5-ethenyl-5-methyl-1,3-oxazolidine-2,4-dione
chebi:83732 ,
CHEMBL513221
AKOS000545958
NCGC00163961-05
NCGC00163961-06
NCGC00163961-04
NCGC00163961-03
tox21_301101
NCGC00255001-01
dtxcid002361
dtxsid4022361 ,
cas-50471-44-8
NCGC00259709-01
tox21_202160
unii-jj258ezn1i
jj258ezn1i ,
3-(3,5-dichlorphenyl)-5-methyl-5-vinyl-1,3-oxazolidin-2,4-dion
ronilan 50wp
FT-0630633
vinclozolin [iso]
vinclozolin, (+/-)-
(+/-)-3-(3,5-dichlorophenyl)-5-ethenyl-5-methyl-2,4-oxazolidinedione
vinclozolin [mi]
vinclozolin [hsdb]
SCHEMBL21851
ronilon
ronilan fl (salt/mix)
oxazolidinedione, 3-(3,5-dichlorophenyl)-5-ethenyl-5-methyl-
vinclozalin
mascot contact turf fungicide
vinclozlin
3-(3,5-dichlorophenyl)-5-methyl-5-vinyl-1,3-oxazolidine-2,4-dione #
W-109230
3-(3,5-dichlorophenyl)-5-methyl-5-vinyl-oxazolidine-2,4-dione
3-(3,5-dichlorophenyl)-5-methyl-5-vinyloxazolidine-2,4-dione
vinclozolin, pestanal(r), analytical standard
vinclozolin 10 microg/ml in isooctane
vinclozolin 100 microg/ml in cyclohexane
Q412907
zolidine-2,4-dione
vinclozolin 1000 microg/ml in acetone
AS-82034
(-)-3-(3,5-dichlorophenyl)-5-methyl-5-vinyloxazolidine-2,4-dione
152723-54-1

Research Excerpts

Overview

Vinclozolin is a common dicarboximide fungicide used to protect crops from diseases. It competitively antagonizes the binding of natural androgens to their receptor, disturbing the function of tissues that are sensitive to these hormones.

ExcerptReferenceRelevance
"Vinclozolin is a common dicarboximide fungicide used to protect crops from diseases. "( Gestational vinclozolin exposure suppresses fetal testis development in rats.
Fang, Y; Ge, RS; Huang, J; Li, Y; Li, Z; Lin, H; Ma, F; Pan, P; Tian, L; Wang, Y; Wu, K; Yu, Y, 2020
)
2.38
"Vinclozolin is a pesticide with antiandrogenic activity as an endocrine disruptor compound. "( The antiandrogenic vinclozolin induces differentiation delay of germ cells and changes in energy metabolism in 3D cultures of fetal ovaries.
Barreñada, O; Brieño-Enriquez, MA; Del Mazo, J; González-Sanz, S; Rial, E, 2020
)
2.33
"Vinclozolin (VNZ) is a fungicide that competitively antagonizes the binding of natural androgens to their receptor, disturbing the function of tissues that are sensitive to these hormones, as is the case of the male reproductive organs."( Effects of the endocrine disruptor vinclozolin in male reproduction: a systematic review and meta-analysis†.
Correia, S; Feijó, M; Martins, RVL; Pereira, L; Socorro, S, 2021
)
1.62
"Vinclozolin (VCZ) is a fungicide with antiandrogen activity. "( Vinclozolin-induced mouse penile malformation and "small testis" via miR132, miR195a together with the Hippo signaling pathway.
Fu, H; Yan, Z; Yang, J; Yu, H; Zhang, Y; Zhu, Y, 2021
)
3.51
"Vinclozolin (Vz) is a pollutant found in aquatic environments whose antiandrogenic effects in reproduction are well known in mammals. "( Genotoxic effects of vinclozolin on the aquatic insect Chironomus riparius (Diptera, Chironomidae).
Aquilino, M; Martínez-Guitarte, JL; Sánchez-Argüello, P, 2018
)
2.24
"Vinclozolin (V) is a fungicide with anti-androgenic properties whose metabolism is not fully understood, and data on urinary elimination of either V or its metabolites are limited. "( Analysis of 3',5'-dichloro-2,3,4-trihydroxy-2-methylbutylanilide (DTMBA) as a new potential biomarker of exposure to vinclozolin in urine.
Cruz-Hurtado, M; Escobar-Wilches, DC; López-González, ML; Sierra-Santoyo, A, 2018
)
2.13
"Vinclozolin is a chiral fungicide with potential environmental problems. "( Chiral separation and enantioselective degradation of vinclozolin in soils.
Liu, D; Liu, H; Shen, Z; Sun, M; Wang, P; Zhou, Z, 2014
)
2.09
"Vinclozolin (VZ) is a dicarboximide fungicide widely used on fruits, vegetables and wines, effective against fungi plagues. "( Morphological alterations in the freshwater rotifer Brachionus calyciflorus Pallas 1766 (Rotifera: Monogononta) caused by vinclozolin chronic exposure.
Adabache-Ortíz, A; Alvarado-Flores, J; Rico-Martínez, R; Silva-Briano, M, 2015
)
2.07
"Vinclozolin (VZ) is a pesticide that acts as an anti-androgen to impair reproduction in mammals. "( Transcripts of genes encoding reproductive neuroendocrine hormones and androgen receptor in the brain and testis of goldfish exposed to vinclozolin, flutamide, testosterone, and their combinations.
Alavi, SM; Golshan, M; Habibi, HR, 2016
)
2.08
"Vinclozolin is a fungicide used in agriculture that can reach aquatic ecosystems and affect the organisms living there. "( Vinclozolin alters the expression of hormonal and stress genes in the midge Chironomus riparius.
Aquilino, M; Martínez-Guitarte, JL; Sánchez-Argüello, P, 2016
)
3.32
"Vinclozolin is a dicarboxymide fungicide that presents antiandrogenic properties through its two hydrolysis products M1 and M2, which bind to the androgen receptor. "( Biotransformation of vinclozolin in rat precision-cut liver slices: comparison with in vivo metabolic pattern.
Bursztyka, J; Cravedi, JP; Debrauwer, L; Jaeg, JP; Jouanin, I; Perdu, E, 2008
)
2.11
"Vinclozolin (V) is a fungicide with antiandrogenic properties. "( Pharmacokinetics and dosimetry of the antiandrogen vinclozolin after oral administration in the rat.
Barton, HA; Castañeda-Hernández, G; Harrison, RA; Hughes, MF; Sierra-Santoyo, A, 2008
)
2.04
"Vinclozolin is an endocrine-disrupting chemical (EDC) that binds with high affinity to the androgen receptor (AR) and blocks the action of gonadal hormones on male reproductive organs. "( Vinclozolin exposure in utero induces postpubertal prostatitis and reduces sperm production via a reversible hormone-regulated mechanism.
Aleksova, J; Cowin, PA; Foster, PM; Gold, E; O'Bryan, MK; Risbridger, GP; Scott, HS, 2010
)
3.25
"Vinclozolin (VIN) is an antiandrogenic model substance as well as a common fungicide that can affect the endocrine system of vertebrates. "( An environmentally relevant endocrine-disrupting antiandrogen, vinclozolin, affects calling behavior of male Xenopus laevis.
Hoffmann, F; Kloas, W, 2010
)
2.04
"Vinclozolin (V) is a fungicide used in agricultural settings. "( In vitro metabolism of the anti-androgenic fungicide vinclozolin by rat liver microsomes.
Angeles-Soto, E; de Lourdes López-González, M; Harrison, RA; Hughes, MF; Sierra-Santoyo, A, 2012
)
2.07
"Vinclozolin is a systemic dicarboximide fungicide that is used on fruits, vegetables, ornamental plants, and turf grass. "( Effect of the anti-androgenic endocrine disruptor vinclozolin on embryonic testis cord formation and postnatal testis development and function.
Skinner, MK; Suzuki, H; Uzumcu, M,
)
1.83
"Vinclozolin (VCZ) is a systemic dicarboximide fungicide with antiandrogenic activity. "( Reproductive disorders in pubertal and adult phase of the male rats exposed to vinclozolin during puberty.
Ahn, B; Do, JC; Hong, JT; Kim, YC; Lee, BJ; Lee, YS; Nam, SY; Yu, WJ; Yun, YW, 2004
)
1.99
"Vinclozolin is a fungicide that has been shown to cause Leydig cell tumors and atrophy of the accessory sex glands in adult rodents. "( Mode of action: inhibition of androgen receptor function--vinclozolin-induced malformations in reproductive development.
Cummings, A; Kavlock, R,
)
1.82
"Vinclozolin is a fungicide that has been reported to have anti-androgenic effects in rats. "( Embryonic exposure to the fungicide vinclozolin causes virilization of females and alteration of progesterone receptor expression in vivo: an experimental study in mice.
Agras, K; Baskin, LS; Buckley, J; Willingham, E, 2006
)
2.05
"Vinclozolin is a fungicide thought to be an environmental antiandrogen, which disrupts masculine sexual behavior when administered to rabbits during development."( Sex differences and the development of the rabbit brain: effects of vinclozolin.
Bisenius, ES; Sammonds, GE; Tobet, S; Veeramachaneni, DN, 2006
)
1.29
"Vinclozolin is a well-characterized antiandrogenic fungicide. "( Peripubertal exposure to the antiandrogenic fungicide, vinclozolin, delays puberty, inhibits the development of androgen-dependent tissues, and alters androgen receptor function in the male rat.
Gray, LE; Kelce, WR; Lambright, C; Monosson, E; Ostby, J,
)
1.82
"Vinclozolin is a fungicide whose metabolites are androgen receptor (AR) antagonists. "( Characterization of the period of sensitivity of fetal male sexual development to vinclozolin.
Gray, LE; LeBlanc, GA; Ostby, JS; Wolf, CJ, 2000
)
1.98
"Vinclozolin is a fungicide used on food crops with human exposure estimated at approximately 2 microg/kg/day from ingestion; occupational exposure, however, may be greater. "( Behavioral responses of rats exposed to long-term dietary vinclozolin.
Delclos, KB; Ferguson, SA; Flynn, KM; Newbold, RR, 2001
)
2
"Vinclozolin is an androgen receptor antagonist that inhibits androgen-dependent tissue growth in vivo."( Androgens and environmental antiandrogens affect reproductive development and play behavior in the Sprague-Dawley rat.
Gray, LE; Hotchkiss, AK; Ostby, JS; Vandenburgh, JG, 2002
)
1.04

Effects

Vinclozolin (Vin) has been shown to be an anti-androgen affecting male offspring in rats in utero. Its mechanism of action may be mediated by inhibition of androgenic receptor action.

ExcerptReferenceRelevance
"Vinclozolin (VCZ) has been identified as a broad-spectrum fungicide and an environmental endocrine disruptor. "( Accentuated Hippo pathway and elevated miR-132 and miR-195a lead to changes of uteri and ovaries in offspring mice following prenatal exposure to vinclozolin.
Fu, H; Xin, B; Yan, Z; Yang, J; Zhu, Y, 2023
)
2.55
"As vinclozolin has been shown to induce clear anti-androgenic effects in offspring following treatment with 100mg/(kg bw day) during entire gestation, the lack of effects in this study indicates that the window of sensitivity for anti-androgenic effects is from days 16-20 p.c."( Vinclozolin--the lack of a transgenerational effect after oral maternal exposure during organogenesis.
Buesen, R; Kaufmann, W; Schneider, S; van Ravenzwaay, B, 2008
)
2.3
"Vinclozolin (Vin) has been shown to be an anti-androgen affecting male offspring in rats in utero, and its mechanism of action may be mediated by inhibition of androgenic receptor action."( Male adolescent exposure to endocrine-disrupting pesticides: vinclozolin exposure in peripubertal rabbits.
Cheever, KL; Clark, JC; Marlow, KL; Moorman, WJ; Schrader, SM; Skaggs, SR; Turner, TW, 2000
)
1.27

Actions

ExcerptReferenceRelevance
"Vinclozolin was the lower embryo toxic compound."( Linking embryo toxicity with genotoxic responses in the freshwater snail Physa acuta: single exposure to benzo(a)pyrene, fluoxetine, bisphenol A, vinclozolin and exposure to binary mixtures with benzo(a)pyrene.
Aparicio, N; Fernández, C; Sánchez-Argüello, P, 2012
)
1.3

Treatment

Vinclozolin treatment delayed pubertal maturation (at 30 and 100 mg kg-1 day-1) and retarded sex accessory gland and epididymal growth. The decreased estrogen-to-androgen ratios reported might be due to an increase of peripheral (adrenal) steroidogenesis.

ExcerptReferenceRelevance
"In vinclozolin-treated animals, the decreased estrogen-to-androgen ratios reported might be due to an increase of peripheral (adrenal) steroidogenesis."( Characterization of endocrine-disrupting chemicals based on hormonal balance disruption in male and female adult rats.
Arnaud, M; Barouki, R; Cren-Olivé, C; Lecomte, A; Lemazurier, E; Quignot, N; Robidel, F; Tournier, M, 2012
)
0.89
"Vinclozolin treated gonads had significantly fewer cords (P < 0.05) and the histology of the cords that formed were abnormal as compared to vehicle-treated organs."( Effect of the anti-androgenic endocrine disruptor vinclozolin on embryonic testis cord formation and postnatal testis development and function.
Skinner, MK; Suzuki, H; Uzumcu, M,
)
1.11
"The vinclozolin-treated male rats showed a reduction of epididymis and accessory sex organ weights and an alteration of hormonal patterns."( Repeated 28-day oral toxicity study of vinclozolin in rats based on the draft protocol for the "Enhanced OECD Test Guideline No. 407" to detect endocrine effects.
Choi, KS; Han, SY; Kang, IH; Ki, HY; Kim, TS; Moon, HJ; Shin, JH, 2006
)
1.08
"Vinclozolin treatment at 50 and 100 mg kg-1 day-1 induced reproductive tract malformations and reduced ejaculated sperm numbers and fertility."( Environmental antiandrogens: low doses of the fungicide vinclozolin alter sexual differentiation of the male rat.
Gray, LE; Kelce, WR; Monosson, E; Ostby, J,
)
1.1
"Vinclozolin treatment delayed pubertal maturation (at 30 and 100 mg kg-1 day-1) and retarded sex accessory gland and epididymal growth."( Peripubertal exposure to the antiandrogenic fungicide, vinclozolin, delays puberty, inhibits the development of androgen-dependent tissues, and alters androgen receptor function in the male rat.
Gray, LE; Kelce, WR; Lambright, C; Monosson, E; Ostby, J,
)
1.1

Toxicity

Vinclozolin administered to pregnant Wistar and Long-Evans rats from day 14 postcoitum to day 3 postpartum at 200 mg/kg body wt/day was maternally toxic. Major adverse effects on sex-specific organs in male offspring were seen.

ExcerptReferenceRelevance
" Several cytochrome P450 (CYP)-dependent reactions have been monitored in liver, kidney and lung microsomes of male and female Swiss Albino CD1 mice in order to ascertain certain toxic non-genetic properties (related to carcinogenesis) of Vinclozolin."( The genetic and non-genetic toxicity of the fungicide Vinclozolin.
Cantelli Forti, G; Fimognari, C; Hrelia, P; Maffei, F; Mesirca, R; Paolini, M; Pozzetti, L; Vigagni, F, 1996
)
0.72
"Vinclozolin administered to pregnant Wistar and Long-Evans rats from day 14 postcoitum to day 3 postpartum at 200 mg/kg body wt/day was maternally toxic (reduced food consumption and body weight gain) and increased perinatal mortality; major adverse effects on sex-specific organs in male offspring were seen (reduced anogenital distance and index; persistence of nipples/areolas into adulthood; hypospadic penis; penile hypoplasia or development of a vaginal pouch; transient paraphimosis; hypoplasia and chronic inflammation of epididymides, prostate, seminal vesicles, and coagulating glands; and also testicular tubular atrophy and chronic inflammation of the urinary bladder in some Long-Evans) with isolated inflammation-related deaths due to pyelonephritis."( Pre- and postnatal oral toxicity of vinclozolin in Wistar and Long-Evans rats.
Gembardt, C; Hellwig, J; Mayer, M; van Ravenzwaay, B, 2000
)
2.02
" Iprodione was more toxic than vinclozolin."( Cytotoxicity of the dicarboximide fungicides, vinclozolin and iprodione, in rat hepatoma-derived Fa32 cells.
Dierickx, PJ, 2004
)
0.87
" Embryo toxic responses showed a clear dose-related tendency whereas no clear dose-dependent effect was observed in micronucleus induction."( Linking embryo toxicity with genotoxic responses in the freshwater snail Physa acuta: single exposure to benzo(a)pyrene, fluoxetine, bisphenol A, vinclozolin and exposure to binary mixtures with benzo(a)pyrene.
Aparicio, N; Fernández, C; Sánchez-Argüello, P, 2012
)
0.58
" The IVF/IVC system detected significant adverse effect of high dose of vinclozolin on blastocyst formation, which was not detected by conventional measures such as litter size or sperm motility and viability."( Combined in vitro fertilization and culture (IVF/IVC) in mouse for reprotoxicity assessment of xenobiotic exposure.
Callesen, H; Foldager, L; Kristensen, KK; Larsen, K; Liu, Y; Pedersen, HS; Sørensen, MT, 2019
)
0.75
" Perturbations of these endpoints are described as common key events in adverse outcome pathways (AOPs) specific for DNT."( Combining in vitro assays and mathematical modelling to study developmental neurotoxicity induced by chemical mixtures.
Bal-Price, A; Bopp, SK; Carpi, D; Mendoza-de Gyves, E; Paini, A; Pistollato, F; Worth, A, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" M5, the most abundant V metabolite, may be used as an exposure biomarker for pharmacokinetic modeling."( Pharmacokinetics and dosimetry of the antiandrogen vinclozolin after oral administration in the rat.
Barton, HA; Castañeda-Hernández, G; Harrison, RA; Hughes, MF; Sierra-Santoyo, A, 2008
)
0.6

Dosage Studied

Study aimed to identify a dosing regime that would induce malformations in all of the male offspring. Pregnant rabbits were dosed orally with vinclozolin (10 mg/kg body weight) or carrot paste vehicle once daily for 6 wk beginning at midgestation.

ExcerptRelevanceReference
" 75, 198-207, 1997) have suggested that dosing chemicals to newly weaned male rats for 1 month may yield a useful assay for antiandrogens."( The weanling male rat as an assay for endocrine disruption: preliminary observations.
Ashby, J; Lefevre, PA, 1997
)
0.3
" Here, we present information on the reproductive effects of oral treatment with low dosage levels of V during sexual differentiation of the male rat."( Environmental antiandrogens: low doses of the fungicide vinclozolin alter sexual differentiation of the male rat.
Gray, LE; Kelce, WR; Monosson, E; Ostby, J,
)
0.38
" Serum luteinizing hormone (LH; significant at all dosage levels) and testosterone and 5 alpha-androstane, 3 alpha, 17 beta-diol (at 100 mg kg-1 day-1) levels were increased."( Peripubertal exposure to the antiandrogenic fungicide, vinclozolin, delays puberty, inhibits the development of androgen-dependent tissues, and alters androgen receptor function in the male rat.
Gray, LE; Kelce, WR; Lambright, C; Monosson, E; Ostby, J,
)
0.38
" The objectives of this study were to determine the most sensitive period of fetal development to antiandrogenic effects of vinclozolin and to identify a dosing regime that would induce malformations in all of the male offspring."( Characterization of the period of sensitivity of fetal male sexual development to vinclozolin.
Gray, LE; LeBlanc, GA; Ostby, JS; Wolf, CJ, 2000
)
0.74
" A 2-month dosing period was therefore initiated at 3 months of age and carried through to the 4th month."( Male adolescent exposure to endocrine-disrupting pesticides: vinclozolin exposure in peripubertal rabbits.
Cheever, KL; Clark, JC; Marlow, KL; Moorman, WJ; Schrader, SM; Skaggs, SR; Turner, TW, 2000
)
0.55
" For the current studies, male rats were dosed for 15 days via oral gavage and euthanized on the morning of test day 15."( Evaluation of a 15-day screening assay using intact male rats for identifying antiandrogens.
Frame, SR; Ladics, GS; O'Connor, JC, 2002
)
0.31
" The data were modeled to determine the dose-response surface of M2 and androgen receptor concentrations at different 5alpha-dihydrotestosterone levels and the relationship of the 3 components to the response."( Response-surface modeling of the effect of 5alpha-dihydrotestosterone and androgen receptor levels on the response to the androgen antagonist vinclozolin.
Euling, SY; Gennings, C; Kelce, WR; Kemppainen, JA; Kimmel, CA; Wilson, EM, 2002
)
0.52
" Dosing the animals with a combination of a 1:1 mixture of vinclozolin and procymidone resulted in a weight reduction in the reproductive organs and an increase of serum LH and FSH as early as with 10 mg/kg combined dose."( The combined effects of vinclozolin and procymidone do not deviate from expected additivity in vitro and in vivo.
Dalgaard, M; Lam, HR; Nellemann, C; Vinggaard, AM, 2003
)
0.87
" At the dosage levels used herein, V + TP-treated male offspring had less well-developed nipples as infants and adults and a lower incidence of ectopic testis than did the V group."( Interactive effects of vinclozolin and testosterone propionate on pregnancy and sexual differentiation of the male and female SD rat.
Gray, LE; LeBlanc, GA; Wolf, CJ, 2004
)
0.63
" A subset of testosterone treated animals was then dosed with 200 mg/kg of either fungicide in corn oil."( Gene expression analysis in the ventral prostate of rats exposed to vinclozolin or procymidone.
Gray, LE; Rosen, MB; Schmid, JE; Wilson, VS,
)
0.37
"The aim of this study was to assess whether the joint effects of three androgen receptor antagonists (vinclozolin, flutamide, procymidone) on male sexual differentiation after in utero and postnatal exposures can be predicted based on dose-response data of the individual chemicals."( Combined exposure to anti-androgens exacerbates disruption of sexual differentiation in the rat.
Axelstad, M; Christiansen, S; Dalgaard, M; Hass, U; Kortenkamp, A; Metzdorff, SB; Scholze, M; Vinggaard, AM, 2007
)
0.55
" Changes in anogenital distance (AGD) and nipple retention (NR) in male offspring rats were chosen as end points for extensive dose-response studies."( Combined exposure to anti-androgens exacerbates disruption of sexual differentiation in the rat.
Axelstad, M; Christiansen, S; Dalgaard, M; Hass, U; Kortenkamp, A; Metzdorff, SB; Scholze, M; Vinggaard, AM, 2007
)
0.34
" Pregnant Wistar rats were dosed by oral gavage with vinclozolin 0, 4 or 100mg/(kg bw day) on days 6-15 post coitum (p."( Vinclozolin--the lack of a transgenerational effect after oral maternal exposure during organogenesis.
Buesen, R; Kaufmann, W; Schneider, S; van Ravenzwaay, B, 2008
)
2.04
" Rats were dosed during pregnancy with antiandrogens singly or in pairs at dosage levels equivalent to about one half of the ED50 for hypospadias or epididymal agenesis."( Cumulative effects of in utero administration of mixtures of "antiandrogens" on male rat reproductive development.
Furr, JR; Gray, LE; Hotchkiss, AK; Howdeshell, KL; Lambright, CR; Rider, CV; Wilson, VS, 2009
)
0.35
" Sprague-Dawley rats were dosed by gavage with vinclozolin at 0, 10, 30, 60, and 100 mg/kg/day with and without 50 mg iprodione/kg/day from postnatal day (PND) 23 to 55-57 (n = 8 per group)."( Cumulative and antagonistic effects of a mixture of the antiandrogens vinclozolin and iprodione in the pubertal male rat.
Blystone, CR; Cardon, MC; Furr, J; Gray, LE; Hartig, PC; Lambright, CS; Rider, CV; Wilson, VS, 2009
)
0.84
" In the present study, in an aim to further examine the disruption of GnRH neurones by foetal vinclozolin exposure, pregnant rabbits were dosed orally with vinclozolin, flutamide or carrot paste vehicle for the last 2 weeks of gestation."( Prenatal exposure to vinclozolin disrupts selective aspects of the gonadotrophin-releasing hormone neuronal system of the rabbit.
Aurand, ER; Gore, AC; Hartshorn, CA; Noel, ML; Palmer, JS; Roselli, CE; Tobet, SA; Veeramachaneni, DN; Wadas, BC, 2010
)
0.9
" In all binary mixture studies, rats were dosed during pregnancy with chemicals, singly or in pairs, at dosage levels equivalent to approximately one-half of the ED50 for hypospadias or epididymal agenesis."( Cumulative effects of in utero administration of mixtures of reproductive toxicants that disrupt common target tissues via diverse mechanisms of toxicity.
Furr, JR; Gray, LE; Rider, CV; Wilson, VS, 2010
)
0.36
" Parental Wistar rats (n=25/sex/dose) were dosed pre-mating (males 4, females 2 weeks) through F1 offspring weaning (postnatal day PND21); F1 dosing continued through PND70."( Vinclozolin: a feasibility and sensitivity study of the ILSI-HESI F1-extended one-generation rat reproduction protocol.
Kaufmann, W; Schneider, S; Strauss, V; van Ravenzwaay, B, 2011
)
1.81
" Dams were dosed with Vinclozolin at 0, 4 or 100mg/kg bw/d on gestation days 6-15."( Vinclozolin--no transgenerational inheritance of anti-androgenic effects after maternal exposure during organogenesis via the intraperitoneal route.
Buesen, R; Gröters, S; Marxfeld, H; Schneider, S; van Ravenzwaay, B, 2013
)
2.15
" This analysis focused on vinclozolin owing to the availability of a comprehensive suite of dose-response data (NOAEL, reference dose, and human exposure estimates) for both conventional and epigenetic endpoints."( Are we ready to consider transgenerational epigenetic effects in human health risk assessment?
Alyea, RA; Gollapudi, BB; Rasoulpour, RJ, 2014
)
0.7
" Interactions were analyzed by direct comparison between experimental and estimated dose-response curves assuming CA, followed by an analysis by the isobole method and the toxic unit approach."( Additive and synergistic antiandrogenic activities of mixtures of azol fungicides and vinclozolin.
Christen, V; Crettaz, P; Fent, K, 2014
)
0.63
" Severity scores were tightly correlated with histologically determined urethral length and both techniques showed similar dose-response relationships."( A validated protocol to quantify severity of male urogenital feminization using the MOUSE (Mouse objective urethral severity evaluation).
Amato, CM; McCoy, KA, 2016
)
0.43
" The data generated clarify whether a non-monotonic dose-response relationship exists to enhance the current debate about the regulation of endocrine disruptors."( Investigations of putative reproductive toxicity of low-dose exposures to vinclozolin in Wistar rats.
Buesen, R; Flick, B; Fussell, KC; Gröters, S; Melching-Kollmuss, S; Schneider, S; Strauss, V; van Ravenzwaay, B, 2017
)
0.69
" A non-monotonic dose-response relationship was not evident."( Investigations on the dose-response relationship of combined exposure to low doses of three anti-androgens in Wistar rats.
Buesen, R; Fussell, KC; Gröters, S; Jiang, X; Melching-Kollmuss, S; Schneider, S; Strauss, V; van Ravenzwaay, B, 2017
)
0.46
" The Vz exposures affected the DNA integrity in this organism, since a dose-response relationship occurred, with DNA strand breaks significantly increased with increased dose for tail area, olive moment and tail moment parameters."( Genotoxic effects of vinclozolin on the aquatic insect Chironomus riparius (Diptera, Chironomidae).
Aquilino, M; Martínez-Guitarte, JL; Sánchez-Argüello, P, 2018
)
0.8
" DTMBA approximately represented 88% of the total excreted metabolites, it was easily detected up to 168 h after dosing and its half-lives were 21."( Analysis of 3',5'-dichloro-2,3,4-trihydroxy-2-methylbutylanilide (DTMBA) as a new potential biomarker of exposure to vinclozolin in urine.
Cruz-Hurtado, M; Escobar-Wilches, DC; López-González, ML; Sierra-Santoyo, A, 2018
)
0.69
" To account for differences in total doses mice experienced due to differences in length of dosing time, we compared animals that received the same total doses."( Organizational effects of the antiandrogen, vinclozolin, on penis development in the mouse.
Amato, CM; Boyd, M; McCoy, KA; Yang, J, 2018
)
0.74
" Overall, the low dosage used only affected weakly most of classical reproductive endpoints."( Different exposure windows to low doses of genistein and/or vinclozolin result in contrasted disorders of testis function and gene expression of exposed rats and their unexposed progeny.
Auger, J; Bennani Smires, B; Bergès, R; Canivenc-Lavier, MC; Eustache, F; Moison, D; Vaiman, D, 2020
)
0.8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
dicarboximideAn imide in which the two acyl substituents on nitrogen are carboacyl groups.
dichlorobenzeneAny member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
oxazolidinoneAn oxazolidine containing one or more oxo groups.
olefinic compoundAny organic molecular entity that contains at least one C=C bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency54.63863.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency44.28750.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency23.34600.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency18.06550.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID588516; AID743035; AID743040; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency64.46460.000657.913322,387.1992AID1259377; AID1259378
progesterone receptorHomo sapiens (human)Potency22.94710.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency59.05570.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency27.36600.000817.505159.3239AID1159527; AID1159531; AID588544
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency66.19470.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency53.30300.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency44.41970.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743078
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency68.17130.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency12.64370.001628.015177.1139AID1224843; AID1224895
activating transcription factor 6Homo sapiens (human)Potency54.63860.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency54.638619.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency23.07910.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency114.58300.039147.5451146.8240AID1224845; AID1224896
heat shock protein beta-1Homo sapiens (human)Potency21.75200.042027.378961.6448AID743210
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency68.58960.000627.21521,122.0200AID651741
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency68.17130.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency44.66840.002319.595674.0614AID651743
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency68.17130.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID1110800Antifungal activity against Botryotinia fuckeliana assessed as growth inhibition at 1 mg/ml after 72 hr by paper disk diffusion method2004Farmaco (Societa chimica italiana : 1989), Sep, Volume: 59, Issue:9
1-Phenyl-3-toluyl-4-[ortho-1'-(N-ethyl-2'-methylpropylamine)]phenylpyrazole, synthesis and evaluation of the in vitro antifungal activity against Botrytis cinerea and Fusarium oxysporum.
AID1110799Antifungal activity against Fusarium oxysporum assessed as growth inhibition at 1 mg/ml after 72 hr by paper disk diffusion method2004Farmaco (Societa chimica italiana : 1989), Sep, Volume: 59, Issue:9
1-Phenyl-3-toluyl-4-[ortho-1'-(N-ethyl-2'-methylpropylamine)]phenylpyrazole, synthesis and evaluation of the in vitro antifungal activity against Botrytis cinerea and Fusarium oxysporum.
AID417419Antifungal activity against Saccharomyces cerevisiae ATCC 201388 carrying pYES2-HIK1 in SD/-Ura medium after 48 hrs by CLSI susceptibility test2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
The antifungal polyketide ambruticin targets the HOG pathway.
AID417422Antifungal activity against Saccharomyces cerevisiae ATCC 201388 carrying pYES2 in SG/-Ura medium after 48 hrs by CLSI susceptibility test2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
The antifungal polyketide ambruticin targets the HOG pathway.
AID376577Antifungal activity against Colletotrichum fragariae assessed as zone of inhibition2000Journal of natural products, Aug, Volume: 63, Issue:8
A new 2D-TLC bioautography method for the discovery of novel antifungal agents To control plant pathogens.
AID417301Antifungal activity against Saccharomyces cerevisiae ATCC 201388 carrying pYES2 in SD/-Ura medium after 48 hrs by CLSI susceptibility test2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
The antifungal polyketide ambruticin targets the HOG pathway.
AID417423Antifungal activity against Saccharomyces cerevisiae ATCC 201388 carrying pYES2-HIK1 in SG/-Ura medium after 48 hrs by CLSI susceptibility test2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
The antifungal polyketide ambruticin targets the HOG pathway.
AID417424Antifungal activity against Saccharomyces cerevisiae ATCC 201388 carrying pYES2-hik1-H736V in SG/-Ura medium after 48 hrs by CLSI susceptibility test2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
The antifungal polyketide ambruticin targets the HOG pathway.
AID417421Antifungal activity against Saccharomyces cerevisiae ATCC 201388 carrying pYES2-hik1-D1153E in SD/-Ura medium after 48 hrs by CLSI susceptibility test2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
The antifungal polyketide ambruticin targets the HOG pathway.
AID417420Antifungal activity against Saccharomyces cerevisiae ATCC 201388 carrying pYES2-hik1-H736V in SD/-Ura medium after 48 hrs by CLSI susceptibility test2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
The antifungal polyketide ambruticin targets the HOG pathway.
AID417425Antifungal activity against Saccharomyces cerevisiae ATCC 201388 carrying pYES2-hik1-D1153E in SG/-Ura medium after 48 hrs by CLSI susceptibility test2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
The antifungal polyketide ambruticin targets the HOG pathway.
AID468443Inhibition of human FAAH at 1 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (278)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (2.16)18.7374
1990's31 (11.15)18.2507
2000's110 (39.57)29.6817
2010's112 (40.29)24.3611
2020's19 (6.83)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.58 (24.57)
Research Supply Index5.68 (2.92)
Research Growth Index5.33 (4.65)
Search Engine Demand Index54.53 (26.88)
Search Engine Supply Index2.16 (0.95)

This Compound (36.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews12 (4.12%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other279 (95.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]